Page 190 - Traditional Medicine Systems of BIMSTEC Member States – 2023 Report
P. 190

Among  47,827  participants, the  trial  group  (n =  101)  was evaluated  with

                                 the positivity percentage of IgG COVID-19 and Immune Status Questionnaire
                                 (ISQ) scores as a primary outcome and the WHO Quality of Life Brief Version

                                 (QOL BREF) scores along with haematological parameters as a secondary
                                 outcome in comparison to the control group (n = 71).

                                     The data showed that the percentage of COVID-19 IgG positivity was
                                 significantly lower in the trial group (17.5 %) as compared to the control

                                 group (39.4 %, p = 0.003), indicating  the lower risk (55.6%) of COVID-19
                                 infection  in  the  trial  group. The  decreased  incidence (5.05%)  and  reduced

                                 mortality percentage (0.44%) of COVID-19 among Delhi police officers
                                 during  peak  times  of  the  pandemic  also  corroborate  our  findings. The  ISQ

                                 score and WHO-QOL BREF tool analysis showed the improved scores in
                                 the trial group when compared with the controls. Furthermore, no dysregulated

                                 blood profile and no increase in inflammation markers like C-reactive protein,
                                 erythrocyte sedimentation rate, Interleukin-6 (IL-6) were observed in the trial

                                 group. However, significantly enhanced (p = 0.027) IL-6 levels and random
                                 blood sugar levels were found in the control group (p = 0.032), compared

                                 to a trial group (p = 0.165) post-intervention. Importantly, the control group
                                                                                                           +
                                 showed  more  significant  (p =  0.0001)  decline  in  lymphocyte  subsets  CD3
                                                          +
                                                                                        +
                                 (% change = 21.04), CD4  (% change = 20.34) and CD8  (% change = 21.54)
                                 levels  than  in  trial  group,  confirming  more  severity  of  COVID-19  infection
                                 in the control group.
              T raditional Medicine Systems of BIMSTEC Member States – 2023 Report
                                     The  AYURAKSHA kit is associated with reduced COVID-19 positivity

                                 and with a better quality of life among the trial group. Hence, the study
                                 encourages in-depth research and future integration of traditional medicines

                                 for the prevention of the COVID-19 pandemic.
                             o)  Efficacy of add-on  Ayurveda and  Yoga intervention in health care

                                 workers of tertiary care hospital during COVID-19: Randomised
                                 controlled trial

                                     This study aimed to evaluate the safety and prophylactic efficacy of add-
                                 on  Comprehensive Ayurveda  and  mindfulness-based Yoga  (CAY)  regimen  to

                                 standard care among HealthCare Workers (HCWs) against COVID-19.










           180






       Untitled-1   180                                                                                         23/2/2567 BE   07:32
   185   186   187   188   189   190   191   192   193   194   195